These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24378784)

  • 1. 2013 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2014 Jan; 13(1):5-7. PubMed ID: 24378784
    [No Abstract]   [Full Text] [Related]  

  • 2. Why is there no generic insulin? Historical origins of a modern problem.
    Greene JA; Riggs KR
    N Engl J Med; 2015 Mar; 372(12):1171-5. PubMed ID: 25785977
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development and perspective for the Biosimilar medicines].
    Takayasu Y; Tsukamoto T
    Nihon Yakurigaku Zasshi; 2016 May; 147(5):303-9. PubMed ID: 27181727
    [No Abstract]   [Full Text] [Related]  

  • 4. Building a wall against biosimilars.
    Nat Biotechnol; 2013 Apr; 31(4):264. PubMed ID: 23563397
    [No Abstract]   [Full Text] [Related]  

  • 5. Sequestration to slash research grants and delay biosimilars.
    Fox JL
    Nat Biotechnol; 2013 Apr; 31(4):271. PubMed ID: 23563405
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction and commentary: Paving the way for biosimilars in oncology.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 8. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investment relief for biotech sector.
    Ledford H
    Nature; 2012 Nov; 491(7424):316. PubMed ID: 23151557
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomedicine. Pharma firms push for sharing of cancer trial data.
    Bhattacharjee Y
    Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
    [No Abstract]   [Full Text] [Related]  

  • 11. The evidence base for new drugs.
    Doshi P; Jefferson T
    BMJ; 2015 Mar; 350():h952. PubMed ID: 25731767
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars in Development Near End of Phase 3 Trials.
    Adams KT
    Manag Care; 2016 Feb; 25(2):16-8. PubMed ID: 27008829
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotech innovators jump on biosimilars bandwagon.
    Moran N
    Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilars battle rages on, Amgen fights both sides.
    Senior M
    Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
    [No Abstract]   [Full Text] [Related]  

  • 15. European Medicines Agency guidelines to increase the pace of biosimilar development.
    Parks L
    Bioanalysis; 2012 Nov; 4(22):2665. PubMed ID: 23346558
    [No Abstract]   [Full Text] [Related]  

  • 16. A need for speed: Signals in drug development.
    Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
    [No Abstract]   [Full Text] [Related]  

  • 17. Preface: issues in biosimilar drug development.
    Yao B; Chi E
    J Biopharm Stat; 2014; 24(6):1137. PubMed ID: 25360866
    [No Abstract]   [Full Text] [Related]  

  • 18. Visions of drug discovery. Cimetidine (Tagamet).
    Mol Interv; 2009 Feb; 9(1):12-3. PubMed ID: 19299658
    [No Abstract]   [Full Text] [Related]  

  • 19. 2011 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
    [No Abstract]   [Full Text] [Related]  

  • 20. State laws on biosimilars may drive up plans' costs.
    Carroll J
    Manag Care; 2013 Apr; 22(4):8-9. PubMed ID: 23682380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.